Molecular Hybridization of Quinoline-2-one and 1,2,3-Triazole: Design, Synthesis, and Cytotoxic Activity Against Pancreatic Cancer Cells
International Journal of Drug Delivery Technology · 07.07.2026 · 16 (63s)
DOI: 10.25258/ijddt.16.63s.152 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 07.07.2026. Verfasst von Deepak Bokka und 7 weiteren Autor:innen.
Abstract (Originalsprache)
A novel series of 1,2,3-triazole-linked quinolin-2-one derivatives, specifically 2-(5-{[(2-oxo-1,2,3,4- tetrahydroquinolin-6-yl)oxy]methyl}-1H-1,2,3-triazol-1-yl)-N-phenylacetamide analogues, were designed and synthesized through a highly efficient copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction, which is known as the click reaction. This key step coupled a 6-propargyloxy-tetrahydroquinolinone scaffold with diverse 2- azido-N-phenylacetamide derivatives, yielding the target hybrids in good to excellent yields (75-88%). The structures of all final compounds (8-12) were rigorously confirmed using comprehensive spectroscopic techniques. ¹H and ¹³C NMR spectra unambiguously verified the formation of the 1,4-disubstituted triazole ring, the methylene linkers, and the integrity of both pharmacophores, while high-resolution mass spectrometry (HRMS) data confirmed the exact molecular mass of each compound with high precision. The in vitro anticancer potential of the library was evaluated against MiaPaCa2 human pancreatic cancer cells using a standardized MTT assay after a 48-hour incubation period, with gemcitabine as the positive control. All compounds exhibited dose-dependent cytotoxic activity, establishing a clear structure-activity relationship (SAR). Compound 8, bearing an unsubstituted phenyl ring, was the most potent (IC₅₀ = 28.22 µM). Halogenation at the ortho (9, IC₅₀ = 32.33 µM) or meta (10, IC₅₀ = 46.32 µM) position reduced activity, while dichloro (11) and methoxy (12) substituents led to a significant drop in potency. Although the series was less active than gemcitabine (IC₅₀ = 4.55 µM), the study successfully validates the triazole-quinolinone molecular hybrid as a promising scaffold, identifying compound 8 as a viable lead for future optimization campaigns aimed at enhancing anticancer efficacy.
Zitieren
APA
Bokka, D., Priya, P., Pavan, P., Sharma, A., Mallappa, M., Kumar, N., Jangir, M., & Sharma, G. C. (2026). Molecular Hybridization of Quinoline-2-one and 1,2,3-Triazole: Design, Synthesis, and Cytotoxic Activity Against Pancreatic Cancer Cells. International Journal of Drug Delivery Technology, 16(63s). https://doi.org/10.25258/ijddt.16.63s.152
Vancouver
Bokka D, Priya P, Pavan P, Sharma A, Mallappa M, Kumar N, et al. Molecular Hybridization of Quinoline-2-one and 1,2,3-Triazole: Design, Synthesis, and Cytotoxic Activity Against Pancreatic Cancer Cells. International Journal of Drug Delivery Technology. 2026;16(63s). doi:10.25258/ijddt.16.63s.152
BibTeX
@article{Bokka2026,
author = {Bokka, Deepak and Priya, Priya and Pavan, Pasupala and Sharma, Anupama and Mallappa, Mallappa and Kumar, Neeraj and Jangir, Mukesh and Sharma, Girish Chandra},
title = {Molecular Hybridization of Quinoline-2-one and 1,2,3-Triazole: Design, Synthesis, and Cytotoxic Activity Against Pancreatic Cancer Cells},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {63s},
doi = {10.25258/ijddt.16.63s.152}
}
EUVIMED